The Venture Codex Logo

The Venture Codex

ACF Investors

Cooper Buildings Arundel Street, Sheffield, South Yorkshire, S1 2NS, United Kingdom

Overview

The Angel CoFund (ACF) is a UK based venture capital fund that co-invests alongside syndicates of sector-smart Angel investors, to fund and scale some of the best high-potential early-stage businesses. The Angel CoFund (ACF) is an active co-investment fund that seeks to achieve consistent returns by partnering with experienced syndicates of angel investors to help fund and scale early-stage businesses. Launched in 2011, ACF’s experienced team has a track record of backing some of the UK’s best success stories through its proven co-investment model, working alongside the unrivalled skills and expertise of the fund’s network of entrepreneurs and private investor partners. Since its launch, the fund has invested over £40M, alongside more than £200M from business angels and other investors, creating a portfolio of more than 80 companies. In many cases, the fund has supported companies through multiple rounds of funding as they have scaled.

Total investments
104
Lead investments
38
Investments · 12mo
6
Active investors
2

Sector focus

  • Finance
  • Venture Capital
Visit website

Investment portfolio

  • Singular Photonics

    Led · Equity · Aug 2026

    Singular Photonics is an Edinburgh-based fabless semiconductor spinout from the University of Edinburgh built on research led by Professor Robert Henderson. The company develops image sensors based on single-photon avalanche diode (SPAD) technology that can detect and precisely time individual photons, enabling high-sensitivity and precise-timing imaging. Singular Photonics combines SPAD detectors with on-chip computation so data can be processed at the point of detection, reducing external data transfer and enabling real-time analysis. It currently offers two commercially available product families, Andarta and Sirona. The company's target application areas include machine vision, industrial automation, physical AI, scientific research and medical imaging. Recent financing of $2.15M is intended to expand engineering capacity and accelerate development and product introductions.

  • Dogtooth Technologies

    Participated · Equity · Jul 2026

    Dogtooth Technologies develops autonomous robotic harvesting systems that combine advanced computer vision, artificial intelligence and precision robotics to identify ripe fruit and harvest delicate crops at commercial scale. The company positions itself at the forefront of embodied AI by applying artificial intelligence to physical machines operating in real-world agricultural environments. Dogtooth has demonstrated commercial readiness and recently delivered systems to Dyson Farming. It aims to help growers address persistent labour shortages, improve operational resilience and increase harvesting capacity. The company plans to expand commercial deployments across the UK and internationally and to strengthen its technology platform. Its recent £14 million growth financing — a mix of equity, grants and a venture leasing facility — is intended to accelerate that commercial rollout and adoption.

  • Silveray

    Participated · Equity · Jun 2026

    Silveray designs and manufactures flexible, ultra-thin X-ray film intended to make imaging sharper, less rigid and more comfortable. Its technology is used in industrial radiography—such as testing pipe integrity in oil and gas and detecting faults in aerospace and automotive components. The company is expanding into healthcare, targeting uses including more accessible, portable and affordable X-ray scans, breast cancer screening, radiotherapy and dental imaging. Silveray plans to scale up production and commercial relationships supported by the £5m raise. The firm intends to grow its team by 50% over the next two years to support this expansion.

  • Orthofuse

    Participated · Seed · Feb 2026

    Orthofuse designs and manufactures next-generation orthopaedic implants using advanced additive manufacturing and novel implant architectures. The company focuses on making procedures more reversible in complex cases, cutting the number of surgical steps while maintaining strong fixation. Its technology is intended to make orthopaedic surgeries safer, more efficient, and to deliver better patient outcomes. Led by CEO and Co-Founder James Scott, Orthofuse is currently refining its product for regulatory approval and early-stage clinical evaluations. The newly raised seed capital will fund further technical development, regulatory readiness, and partnership building. Although still pre-revenue, the company has attracted multiple investor groups, signaling confidence in its approach.

  • Veremark

    Participated · Series B · Feb 2026

    Veremark is a London-based workplace trust company that helps organisations verify, monitor, and manage employee credentials and conduct throughout the employment lifecycle. Its platform combines pre-hire background checks with continuous rescreening, anonymous whistle-blowing tools, and reporting features that surface concerns early to maintain workplace standards. The company can deliver criminal, employment, sanctions, credit, and bankruptcy checks across more than 180 countries and is building digital credentialing services such as its blockchain-based career passport, Verepass, which lets candidates control verified records. Veremark’s revenue run rate grew 300% in 2025, underscoring rapid commercial momentum. It recently bolstered capabilities through the acquisition of specialist provider Agenda Screening Services. Today the firm employs more than 200 people, operates seven offices worldwide, and serves over 6,000 clients including OVO Energy and Schneider Electric. With rising AI-driven fraud risks, Veremark positions its “always-on” trust approach as a critical compliance solution for regulated and multinational employers.

Team